Humanized Mouse and Rat Model Market

The humanized mouse and rat model market is projected to reach USD 349 million by 2028 from USD 259 million in 2023, at a CAGR of 6.2% during the forecast period of 2023 to 2028. Growth in the humanized mouse and rat model market is majorly driven by the rising use of humanized models in drug discovery research, rising demand for personalized medicine, government-funded initiatives for cancer research, increasing R&D activities in pharmaceutical & biotechnology industry. However, the high cost of custom humanized models, and regulatory compliance for ethical use of animal model are expected to restrain the growth of this market during the forecast period.

The global humanized mouse and rat model market is competitive, with THE JACKSON LABORATORY (JAX) (US), Charles River Laboratories (US), and Taconic Biosciences, Inc. (US) together major share of the global market.

To know about the assumptions considered for the study download the pdf brochure

THE JACKSON LABORATORY (JAX) (US)

JAX is a leading player in the humanized mouse and rat model market. The company has a prominent presence across geographies, North America, Europe, and Asia Pacific. Companies that require end-to-end services and models serve as key customers for JAX. The company has built a diverse range of humanized mouse and rat models, with strategic focus on maintaining existing customer/end-user base, strengthening long-term contracts. The company further leverages its position in ancilliary markets such as drug discovery, disease modeling, to sustain market position and broaden offerings around humanized mouse and rat model market.

CHARLES RIVER LABORATORIES (US)

Charles River Laboratories (US) ranks second in terms of market position, attributive to its established range of mice models and rat models in the market. CRL is operational since more than 70 years, and has achieved core competency in vivo biology. The company provides early-stage drug discovery and preclinical development solutions, including  humanized mouse models. Its robust portfolio helps the company to strengthen collaboration with clients—from early lead generation to candidate selection. CRL’s portfolio is inclusive of around 150 different stocks and strains of animal models, the company is engaged in producing and selling the most widely used rodent research model strains and purpose-bred rats and mice. Charles River also provides a variety of related services that are designed to support clients in the use of research models in drug discovery and development.

INOTIV (US)

Inotiv is one of the leading market players in the mice model market. The strength of the company can be attributed to its robust product portfolio as well as a number of acquisitions & partnerships that allows it to market its products worldwide. Inotiv also has a significant geographical footprint in developed countries across North America and Europe. Inotiv entered the mice model market with the acquisition of Envigo. Since this strategic development, the company has worked towards improving its production & distribution capabilities. The company’s revenue grew to USD 547.7 million during the fiscal year 2022 from USD 89.6 million during the fiscal year 2021.

Related Reports:

Humanized Mouse and Rat Model Market by Type (Genetic Models, Cell-based Models (CD34, BLT, PMC), Rat Models), Application (Oncology, Immunology, Neuroscience, Toxicology, Infectious Diseases), End User (Pharma, Biotech) - Global Forecast to 2028

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]